Metraipolis › archive › dc_2ac8f4de507c

Limitations of Guideline-Recommended Risk Stratification in Identifying MASLD Patients for Novel Drug Treatments — Europe PMC PMID:41123302

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41123302
DOI
10.1111/liv.70281
License (as archived)
solo-consultazione
Archived
2026-11-10T05:36:12.394Z
SHA-256 of the archived text
7cc07d71c6d1186aea9b084dad74ca1ad51fa71ab5af1ff764af3aededd38d9a
Stable URL of this page
https://metraipolis.com/documento/dc_2ac8f4de507c

How to cite

Limitations of Guideline-Recommended Risk Stratification in Identifying MASLD Patients for Novel Drug Treatments — Europe PMC PMID:41123302 — Europe PMC (en), https://europepmc.org/article/MED/41123302 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2ac8f4de507c (Metraipolis archive dc_2ac8f4de507c, sha256 7cc07d71c6d1186aea9b084dad74ca1ad51fa71ab5af1ff764af3aededd38d9a)
BibTeX
@misc{dc2ac8f4de507c,
  title = {Limitations of Guideline-Recommended Risk Stratification in Identifying MASLD Patients for Novel Drug Treatments — Europe PMC PMID:41123302},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41123302},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2ac8f4de507c; sha256 7cc07d71c6d1186aea9b084dad74ca1ad51fa71ab5af1ff764af3aededd38d9a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41123302. Agents can read the archived copy with the MCP tool read_document.